5 Stocks Moving The Health Services Industry Upward

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 72 points (0.5%) at 14,749 as of Thursday, April 25, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 2,049 issues advancing vs. 833 declining with 158 unchanged.

The Health Services industry currently sits up 0.5% versus the S&P 500, which is up 0.7%. Top gainers within the industry include Icon ( ICLR), up 9.2%, Zimmer Holdings ( ZMH), up 1.6%, Stryker Corporation ( SYK), up 1.4%, Becton Dickinson ( BDX), up 1.4% and Edwards Life ( EW), up 1.4%. A company within the industry that fell today was Aetna ( AET), up 0.97.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Covidien ( COV) is one of the companies pushing the Health Services industry higher today. As of noon trading, Covidien is up $0.37 (0.56) to $66.67 on average volume Thus far, 847,565 shares of Covidien exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $66.37-$66.76 after having opened the day at $66.44 as compared to the previous trading day's close of $66.30.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $31.5 billion and is part of the health care sector. The company has a P/E ratio of 17.0, below the S&P 500 P/E ratio of 17.7. Shares are up 15.4% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, attractive valuation levels, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Covidien Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, Boston Scientific ( BSX) is up $0.10 (1.36) to $7.46 on heavy volume Thus far, 21.0 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 21.1 million shares. The stock has ranged in price between $7.29-$7.48 after having opened the day at $7.35 as compared to the previous trading day's close of $7.36.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $9.9 billion and is part of the health care sector. Shares are up 28.3% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Boston Scientific as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Boston Scientific Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Medtronic ( MDT) is up $0.73 (1.57) to $47.12 on light volume Thus far, 1.6 million shares of Medtronic exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $46.46-$47.20 after having opened the day at $46.50 as compared to the previous trading day's close of $46.39.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. Medtronic has a market cap of $47.2 billion and is part of the health care sector. The company has a P/E ratio of 14.2, below the S&P 500 P/E ratio of 17.7. Shares are up 13.1% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and attractive valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Medtronic Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Intuitive Surgical ( ISRG) is up $5.12 (1.07) to $482.00 on light volume Thus far, 114,886 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 503,600 shares. The stock has ranged in price between $476.23-$483.29 after having opened the day at $478.60 as compared to the previous trading day's close of $476.88.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $18.9 billion and is part of the health care sector. The company has a P/E ratio of 27.6, above the S&P 500 P/E ratio of 17.7. Shares are down 3.9% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Intuitive Surgical as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Intuitive Surgical Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Express Scripts ( ESRX) is up $0.67 (1.18) to $57.35 on light volume Thus far, 1.5 million shares of Express Scripts exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $56.68-$57.40 after having opened the day at $56.78 as compared to the previous trading day's close of $56.68.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. It offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $46.3 billion and is part of the health care sector. The company has a P/E ratio of 31.5, above the S&P 500 P/E ratio of 17.7. Shares are up 4.5% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, reasonable valuation levels, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Express Scripts Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback